Avinger Initiates Final Wind-Down Process

Avinger US0537348858

The corporate journey for Avinger has reached its definitive conclusion. With shareholder approval for a voluntary dissolution and liquidation already secured, the company's operational business activities have now ceased entirely. Management's sole focus has shifted to an orderly wind-down of corporate affairs. The objective of this final phase is to manage the remaining assets and liabilities in a manner designed to maximize any residual value for equity holders.

This transition into liquidation represents a fundamental strategic pivot. Key development milestones, including the Phase III trial progress for a novel coronary artery disease treatment device, are now being evaluated solely through the lens of asset salability. The central question is whether this intellectual property can still generate meaningful value for creditors and shareholders during the dissolution process. The answer hinges critically on the success and timeline of the asset monetization strategy now underway.

Key aspects of the wind-down plan include:

• A complete focus on asset disposition over operational performance.
• The conclusion of Phase III coronary device trials as part of the liquidation strategy.
• The cessation of regular quarterly financial reporting, effective for the 2026 fiscal year.

Cessation of Routine Financial Updates

Investors must adjust to a new information environment. Following the approval of the liquidation plan in February of last year, the company will no longer adhere to a standard calendar of quarterly earnings releases or analyst conference calls. Any future communications will be primarily dedicated to providing updates on the wind-down progress and the step-by-step completion of the corporate dissolution.

Sector Faces Mounting Regulatory Scrutiny

As Avinger executes its exit, the broader medical technology sector is navigating a period of intensified regulatory pressure. During the current 2026 calendar year, critical regulatory frameworks—including the European Union's Medical Device Regulation (MDR) and the U.S. Quality Management System Regulation (QMSR)—are reaching key implementation deadlines. These evolving standards are reshaping the market landscape for vascular treatments, even as Avinger finalizes its strategic withdrawal.

The effectiveness of monetizing Avinger's remaining patents and technologies will become clearer in the coming months. Subsequent company announcements will relate exclusively to the liquidation's advancement and the eventual distribution of any remaining proceeds to stakeholders.

@ boerse-global.de | US0537348858 AVINGER